Perpignan, France

Jean Bastide


Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2003-2004

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jean Bastide

Introduction

Jean Bastide is a notable inventor based in Perpignan, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with therapeutic applications. With a total of 2 patents, his work focuses on cytotoxic properties that can be utilized in antitumoral medicines.

Latest Patents

Bastide's latest patents include "Phenanthroline-7-one derivatives and their therapeutic uses." This patent describes a pharmaceutical composition that includes an efficient amount of a compound selected among specific formulae. The compounds exhibit interesting cytotoxic properties, leading to their potential use as antitumoral medicines. Another significant patent is for a "Pharmaceutical composition based on polyaromatic compounds." This composition also comprises an efficient amount of a compound selected among designated formulae, showcasing useful cytotoxic properties for therapeutic applications in antitumoral medicine.

Career Highlights

Throughout his career, Jean Bastide has worked with reputable organizations, including Laboratoire L. Lafon. His experience in these companies has allowed him to refine his expertise in pharmaceutical innovations and contribute to the development of effective medicinal compounds.

Collaborations

Bastide has collaborated with notable individuals in his field, including Evelyne Delfourne and Francis Darro. These partnerships have likely enhanced his research and development efforts, leading to impactful innovations.

Conclusion

Jean Bastide's contributions to pharmaceutical inventions demonstrate his commitment to advancing medical science. His innovative patents and collaborations highlight the importance of research in developing effective treatments for serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…